AEON Biopharma (AEON) vs. The Competition Financial Contrast

AEON Biopharma (NASDAQ:AEON) is one of 1,056 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare AEON Biopharma to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, valuation, earnings, risk and profitability.

Institutional and Insider Ownership

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 23.5% of AEON Biopharma shares are owned by company insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares AEON Biopharma and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
AEON Biopharma	N/A	-$36.63 million	3.59
AEON Biopharma Competitors	$1.71 billion	$153.14 million	-5.14

AEON Biopharma’s peers have higher revenue and earnings than AEON Biopharma. AEON Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings for AEON Biopharma and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	0	1	0	3.00
AEON Biopharma Competitors	7691	21012	48662	1213	2.55

AEON Biopharma currently has a consensus price target of $5.00, indicating a potential upside of 673.63%. As a group, “Pharmaceutical preparations” companies have a potential upside of 171.34%. Given AEON Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe AEON Biopharma is more favorable than its peers.

Profitability

This table compares AEON Biopharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
AEON Biopharma Competitors	-3,592.17%	-273.31%	-39.01%

Risk and Volatility

AEON Biopharma has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, AEON Biopharma’s peers have a beta of 3.82, suggesting that their average share price is 282% more volatile than the S&P 500.

Summary

AEON Biopharma beats its peers on 7 of the 13 factors compared.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.